Micro Developing Active

LLY GLP-1 Franchise-Wachstum

Score
0,5
Dynamik
▲ 0,0
Artikel
13
Quellen
4

Zusammenfassung

Ein Artikel gehört zu dieser Erzählung, wenn er über das Wachstum von Eli Lillys GLP-1 Franchise-Medikamenten berichtet.

Verwandte Artikel

US approves new oral weight-loss pill developed by Eli Lilly

The Guardian · Apr 02, 2026
Mixed

Why Eli Lilly Stock Trounced the Market Today

Nasdaq · Apr 01, 2026
Mixed

Eli Lilly vs Novo Nordisk: Which Obesity Drug Stock Is the Better Buy?

Nasdaq · Mär 27, 2026
Mixed

Quellen

US approves new oral weight-loss pill developed by Eli Lilly The Guardian
Eli Lilly Is Bringing AI-Developed Drugs to Market. Should You … Yahoo Finance
Why Eli Lilly Stock Trounced the Market Today Nasdaq
FDA approves Eli Lilly's GLP-1 pill, opening the next phase … CNBC
Eli Lilly and Company (LLY) Continued to Gain from Its … Yahoo Finance
Eli Lilly’s (LLY) Shares Up Since Jim Cramer Said He … Yahoo Finance
GSK (GSK) Shares Up Significantly Since Jim Cramer Said to … Yahoo Finance
Mounjaro maker wants NHS drug price rises in return for … The Guardian
Jefferies Remains a Buy on Eli Lilly and Company (LLY) Yahoo Finance
Eli Lilly vs Novo Nordisk: Which Obesity Drug Stock Is … Nasdaq
Hims & Hers Expands Access To Novo Nordisk's FDA-Approved GLP-1 … Nasdaq
Eli Lilly (LLY) Gained From Growth in its GLP-1 Franchises … Yahoo Finance

Zeitverlauf

Zuletzt aktualisiert Mär 27, 2026